glp-1 vs sglt2 weight loss variability with inhibitors and GLP‐1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities - Brown - 2019 - Obesity Reviews GLP-1 and GIP in Type

Retatrutide is a novel synthetic peptide that functions as a triple receptor agonist, acting on the GLP-1, GIP, and glucagon receptors

GLP-1 drugs may reduce: Frequency of drinking Volume per occasion Desire to drink What this means across the three-tier system Suppliers Monitor changes in premium product demand Evaluate opportunities in lower-ABV and alternative beverages Distributors Watch for shifts in order frequency and product mix Identify regional differences tied to demographics and health trends Retailers On-premise: fewer drinks per visit Off-premise: smaller baskets and substitution effects Why this is a data problem If youre in beverage alcohol, this is a trend you wont see in your dashboardbut you will see it in your data

If you recently titrated up to a higher dose and your constipation dramatically worsened, that dose increase is likely the primary driver

Thanks for reminding people once again

The decision about which weight loss option is appropriate should always be made in partnership with your doctor, who will consider several important factors, including: Your overall health Medical history Current medications The amount of weight youre aiming to lose Your tolerance for certain treatments Always talk with your doctor when exploring effective weight loss options

K., Bartels, E